JLJingran Li

Jingran Li

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jingran Li has a total of 43 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Distribution and extended triage of high-risk human papillomavirus genotyping based on vaginal self-sampling

    by Jingran Li, Chen Yao, Chao Zhao, Mingzhu Li, Ling Li, Zhixin Lin, Zhijun Zhang, Jihong Deng, Rong Liu, Yingying Hu, et al.

    Background: To investigate the overall and type-specific prevalence of high-risk human papillomavirus (HR-HPV) infection in China across different age groups and regions and to evaluate the triage of HPV-positive cases. Methods: A prospective cross-sectional study recruited a total of 20 103 women aged 30–59 years from 13 provinces in China. Self-collected vaginal samples were tested for 14 HR-HPV types using next-generation sequencing or multiplex real-time PCR assays. Results: The five most common types were HPV52, 58, 16, 39 and 51. The prevalence of single-type HR-HPV was 10.70%. The overall proportion of HPV16/18 was 20.67%, with a significant difference observed among provinces (p<0.05). The age-specific prevalence curve of HR-HPV followed a U-shaped pattern from 30 to 59 years, with a lower prevalence observed in women aged 40–44 years (12.35%), which subsequently changed with age. The proportion of women aged 30–34 years with HPV16 (21.59%) was significantly higher than that in other age groups, showing two peaks in young and older women. There was a significantly higher prevalence of HPV16 single-type infection in the youngest group, whereas HPV16 multi-type infection was higher in older women. Among cervical intraepithelial neoplasia grade 2 or higher (CIN)2+ cases, HPV16 infection accounted for 43.98%, HPV18 infection for 7.84%, and other 12 infections for 48.20%. HPV16 had the highest sensitivity for detecting CIN2+, reaching 42.7% among single HPV types, followed by HPV52 and HPV58. When HPV16/18/33 were combined for detection, the sensitivity for detecting CIN2+ increased to 66.67%. Conclusions: The prevalence and genotype distribution of HR-HPV based on vaginal self-sampling varied across different regions and ages in China. HPV16 was more prevalent in both younger and older age groups. Different HPV subtypes have different detection rates for CIN2+, and combining HPV16/18/33 significantly improved the sensitivity for detecting CIN2+.


  • Open Access

    Chinese expert consensus on vaginal self-sampling with high-risk human papillomavirus testing for cervical cancer screening

    by Jingran Li, Ruifang Wu, Mingzhu Li, Hui Du, Long Sui, Beihua Kong, Fanghui Zhao, Linhong Wang, Yun Zhao, Xinfeng Qu, et al.

    Cervical cancer is one of the most common cancers in women globally and remains the leading cause of cancer-related death among women in low- and middle-income countries. It is more prevalent in populations that are unscreened or underscreened. Improving screening coverage presents a global challenge. Self-collected cervical cancer screening allows women to collect samples for high-risk human papillomavirus (HR-HPV) testing on PCR-based tests, effectively increasing screening rates for cervical cancer. In light of the push for HR-HPV testing as a primary cervical cancer screening strategy and considering the current status of cervical cancer screening in China, experts from five academic societies developed a consensus that including the definition, value, advantages, applicable people, screening proposal, tools and methods, process, sampler distribution form, organisational screening model, HPV DNA testing, abnormal results management of vaginal self-sampling, information system construction, management quality control and so on, aims to guide the standardised application of vaginal self-sampling screening, enhance cervical cancer screening coverage in China and advance the efforts to eliminate cervical cancer in the country.


  • Characteristics of genotypes and prevalence of high-risk human papillomavirus in different economic development regions in China

    by Jingran Li, Chao Zhao, Ruifang Wu, Mingzhu Li, Yun Zhao, Hui Du, Ling Li, Zhixin Lin, Zhijun Zhang, Lihui Wei


  • Open Access

    The Fractional CO2 Laser for the Treatment of Genitourinary Syndrome of Menopause: A Prospective Multicenter Cohort Study

    by Jingran Li, Huan Li, Yanfei Zhou, Meiqing Xie, Yali Miao, Luwen Wang, Yan Zhao, Ting Ying, Yan Hu, Yu Chen, et al.

    Background and Objectives: Genitourinary syndrome of menopause (GSM) is a common condition affecting of most postmenopausal women, which greatly impacks the quality of life,and need to treat. This prospective multicenter cohort study aimed to compare the efficacy and safety of the fractional carbon dioxide (CO2) laser with that of topical estrogen for vaginal treatment and relieving symptoms of genitourinary syndrome of menopause (GSM).Study Design/Materials and Methods: This study included 162 postmenopausal patients who received vaginal laser or topical Estriol cream therapy between January 2017 and May 2019 at eight study centers in China. The degree of GSM‐related symptoms (vaginal burning, dryness, and dyspareunia) was evaluated using the Vaginal Health Index score (VHIS) and Visual Analog Scale (VAS) at baseline, 1, 3, 6, and 12 months posttreatment. The primary endpoint was the improvement in vaginal burning, dryness, and dyspareunia at 6 months after treatment. Multivariate logistic regression was used to compare the rate of improvement in the two groups.Results: At baseline, the laser and control groups showed no significant difference in the mean age, time after menopause, and the VHIS (all P > 0.05). In the laser group, compared with baseline, significant differences were seen in the VHIS after the first or second treatment session and at 1, 3, 6, and 12 months posttreatment (P < 0.01). In the control group, compared with baseline, the VHIS showed significant differences after 1, 3, and 6 months of treatment (P < 0.05). However, there was no significant difference after 3 and 6 months of follow‐up between the two groups (P > 0.05). The VHIS scores were significantly higher after 1 month (16.63 ± 2.79 vs. 15.57 ± 2.43) and 12 months (15.72 ± 2.59 vs. 12.12 ± 4.08) of treatment in both the groups (P < 0.05). At 6 months after treatment, both groups showed improvement in vaginal burning, vaginal dryness, and dyspareunia (P > 0.05). The VAS findings at 6 months posttreatment were significantly different when compared with the pretreatment findings (P < 0.001). There were no significant adverse effects in the two groups.Conclusions: Fractional CO2 laser vaginal treatment could be a safe and effective option for treating symptoms of GSM, including vaginal burning, dryness, and dyspareunia. The improvement in symptoms was comparable with that seen with topical estrogen therapy and lasted for at least 6–12 months posttreatment. Lasers Surg. Med. © 2020 Wiley Periodicals LLC